Assisted Reproductive Technology, ART
Conditions
Interventions
Remimazolam group:Intravenous remimazolam toislate injection was performed during anesthesia induction phase for transvaginal oocyte retrieval.
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 45 years old;? 2. ASA physical status classification of I to III; 3. BMI between 18 and 35 kg/m^2; 4. Written informed consent obtained from the patient or the patient's legal representative, and patient without impairments in communication; 5. Female patient scheduled for transvaginal oocyte retrieval under anesthesia.
Exclusion criteria
Exclusion criteria: 1. Patients anticipated to undergo a prolonged oocyte retrieval procedure (=30 minutes) or those necessitating a mid-procedure transition to transabdominal oocyte retrieval; 2. Patients who failed to comply with the prescribed fasting and fluid restrictions; 3. Fever (core body temperature exceeding 37.5 degrees Celsius); 4. Patients assessed to have difficult airways; 5. Severe cardiac dysfunction (180 mmHg or diastolic blood pressure >110 mmHg); 7. Patients in the acute phase of asthma, acute respiratory infection, severe sleep apnea syndrome, or with other pulmonary function abnormalities; 8. Severe hepatic and renal dysfunction; 9. Patients with a history of mental and neurological disorders: such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, etc. ; 10. Long-term use of analgesic/psychotropic medications, past history of drug abuse, or history of drug or alcohol dependence; 11. Patients who received sedative medications within 24 hours prior to surgery; 12. Patients with allergies to multiple drugs, particularly benzodiazepines, opioids, and NSAIDs; 13. Severe visual and auditory impairments; 14. Patients currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achieved successful sedation during transvaginal oocyte retrieval; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse events;Patient's satisfaction score ;Patient's conditions in the recovery room;Patient's follow-up conditions; | — |
Countries
China
Contacts
Public ContactSha Liu
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed